E-ISSN: 2147-2688
A New Marker For Endothelial Function in Peritoneal Dialysis Patients: Apelin
PDF
Cite
Share
Request
Original Article
VOLUME: 51 ISSUE: 1
P: 5-10
March 2013

A New Marker For Endothelial Function in Peritoneal Dialysis Patients: Apelin

Med Bull Haseki 2013;51(1):5-10
DOI: 10.4274/Haseki.808
Serhat Karadağ 1
Meltem Gürsu 2
Savaş Öztürk 2
Ahmet Gürdal 3
Filiz Basınoğlu 4
Zeki Aydın 2
Sami Uzun 2
Abdullah Sumnu 2
Eray Atalay 1
Hüseyin Oflaz 3
Rümeyza Kazancıoğlu 5
1. Kafkas Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Kars, Türkiye
2. Haseki Eğitim ve Araştırma Hastanesi, Nefroloji Kliniği, İstanbul, Türkiye
3. İstanbul Üniversitesi İstanbul Tıp Fakültesi, Kardiyoloji Anabilim Dalı, İstanbul, Türkiye
4. Haseki Eğitim ve Araştırma Hastanesi, Biyokimya Kliniği, İstanbul, Türkiye
5. Bezm-i Alem Vakıf Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı, Nefroloji Bilim Dalı, İstanbul, Türkiye
No information available.
No information available
Received Date: 02.08.2012
Accepted Date: 19.10.2012
PDF
Cite
Share
Request

ABSTRACT

Aim:

The most important cause of death in end-stage renal disease is cardiovascular diseases (CVDs). Endothelial dysfunction (ED) is one of the most important steps in the pathogenesis of CVD Apelin is a peptide recently found to have important roles in cardiovascular and endothelial physiology; and we planned in our study to examine the relationship between apelin and endothelial functions in peritoneal dialysis (PD) patients.

Methods:

Forty-two patients who were followed up in the PD unit at Haseki Training and Research Hospital were involved. Endothelial functions were evaluated ultrasonographically by flow-mediated dilation (FMD) test. Apelin levels and routine laboratory tests were studied from the blood samples obtained from the patients.

Results:

There was a negative correlation between apelin and FMD percentage (r=-0.334, p=0.03). FMD percentage positively correlated with triglyceride and very low density lipoprotein levels (r=0.310, p=0.046; r=0.304, p=0.05, respectively). FMD percentage significantly positively correlated with systolic and diastolic blood pressure (r=0.565,p=<0.001; r=0.560,p=<0.001, respectively). FMD was significantly lower patients with hypertension, compared to those without hypertension (9±5.8 vs. 14.9±6.6; p=0.01).

Conclusion:

ED is closely related with hypertension and lipid profile in PD patients. Apelin may be used as a new marker for ED and a treatment alternative in PD patients.